| Trial ID: | L4983 |
| Source ID: | NCT00545584
|
| Associated Drug: |
Sitagliptin Phosphate
|
| Title: |
Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00545584/results
|
| Conditions: |
Diabetes Mellitus, Non-Insulin-Dependent
|
| Interventions: |
DRUG: sitagliptin phosphate|BEHAVIORAL: Comparator: Diet|BEHAVIORAL: Comparator: Physical Activity
|
| Outcome Measures: |
Primary: Hemoglobin A1c Measurement, Hemoglobin A1c (HbA1c) is a measure of glycated hemoglobin in the blood. HbA1c greater than 6.5% was considered inadequately controlled., Baseline and Week 24 | Secondary: Fasting Plasma Glucose (FPG) Measurement, Generally FPG values of \~5.0-7.2 mmol/L would be considered goal (American Diabetes Association)., Baseline and Week 24
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
1512
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2007-04-01
|
| Completion Date: |
2009-11-19
|
| Results First Posted: |
2011-05-11
|
| Last Update Posted: |
2017-05-12
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00545584
|
